Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$122.84 USD

122.84
1,000,340

-2.16 (-1.73%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $122.86 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?

Style Box ETF report for ISCB

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates

Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.

Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -142.98% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Fulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.

Indrajit Bandyopadhyay headshot

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.

Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate

If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.

Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why

Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end

Clinical Hold on Sarepta's (SRPT) DMD Candidate Lifted by FDA

The FDA lifts the clinical hold placed on Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, being evaluated in the ongoing phase II MOMENTUM study.

Mirati (MRTX) Up 5.3% Since Last Earnings Report: Can It Continue?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust

Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More

Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints

Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.

Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura

Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates

Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.

Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD

Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.